AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Core Insights - AbbVie reported strong financial results for the fourth quarter and full year of 2025, with a notable increase in net revenues and adjusted diluted EPS guidance for 2026 [1] Financial Performance - Fourth-quarter net revenues reached $16.618 billion, marking a 10.0% increase on a reported basis and 9.5% on an operational basis [1] - Full-year net revenues totaled $61.160 billion, an increase of 8.6% on a reported basis and 8.5% on an operational basis [1] - Fourth-quarter diluted EPS was $1.02 on a GAAP basis, while adjusted diluted EPS was $2.71, reflecting an unfavorable impact of $0.71 per share from acquired IPR&D and milestones expense [1] Portfolio Performance - The immunology portfolio generated global net revenues of $30.406 billion for the full year, an increase of 14.0% on a reported basis [1] - The neuroscience portfolio saw a 19.6% increase in global net revenues, totaling $10.767 billion for the full year [1] - The oncology portfolio reported full-year global net revenues of $6.655 billion, a slight increase of 1.5% on a reported basis [1] - The aesthetics portfolio experienced a decline, with full-year global net revenues of $4.860 billion, down 6.1% on a reported basis [1] Recent Developments - AbbVie announced the acquisition of a device manufacturing facility from West Pharmaceutical Services to enhance production capabilities for immunology and neuroscience medicines [1] - An exclusive licensing agreement was established with RemeGen for the development of a novel bispecific antibody, RC148, aimed at treating advanced solid tumors [1] - AbbVie received FDA approval for Epkinly in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma [1] - The company submitted applications for expanded use of Aquipta for migraine treatment and for Rinvoq in treating non-segmental vitiligo [1] 2026 Outlook - AbbVie provided adjusted diluted EPS guidance for 2026 in the range of $14.37 to $14.57, excluding any unfavorable impacts from acquired IPR&D and milestones [1]